Evidence map›Paper›PMID 31031204›Full record

ArticleClinical lung cancer2019

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.

Khinh Ranh Voong, Sarah Z Hazell, Wei Fu, Chen Hu, Cheng Ting Lin, Kai Ding, Karthik Suresh, Jonathan Hayman, Russell K Hales, Salem Alfaifi and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lung cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 5 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 5 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Deep Learning for CT Synthesis in Radiotherapy.Bioengineering (Basel, Switzerland) · 2025
    Review
  13. Review
  14. Article
  15. Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review.The western journal of emergency medicine · 2025
    Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Khinh Ranh VoongDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD. Electronic address: Kvoong1@jhmi.edu.
Sarah Z HazellDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD.
Wei FuDepartment of Oncology, Biostatistics, Johns Hopkins University School of Medicine, Baltimore, MD.
Chen HuDepartment of Oncology, Biostatistics, Johns Hopkins University School of Medicine, Baltimore, MD.
Cheng Ting LinDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.
Kai DingDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD.
Karthik SureshDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Jonathan HaymanDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Russell K HalesDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD.
Salem AlfaifiDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD.
Kristen A MarroneDepartment of Oncology, Johns Hopkins University, Baltimore, MD; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD.
Benjamin LevyDepartment of Oncology, Johns Hopkins University, Baltimore, MD.
Christine L HannDepartment of Oncology, Johns Hopkins University, Baltimore, MD.
David S EttingerDepartment of Oncology, Johns Hopkins University, Baltimore, MD.
Josephine L FelicianoDepartment of Oncology, Johns Hopkins University, Baltimore, MD.
Valerie PetersonDepartment of Oncology, Johns Hopkins University, Baltimore, MD.
Ronan J KellyDepartment of Oncology, Johns Hopkins University, Baltimore, MD.
Julie R BrahmerDepartment of Oncology, Johns Hopkins University, Baltimore, MD; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD.
Patrick M FordeDepartment of Oncology, Johns Hopkins University, Baltimore, MD; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD.
Jarushka NaidooDepartment of Oncology, Johns Hopkins University, Baltimore, MD; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD.
Johns Hopkins University · USBloomberg (United States) · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

purposeTo investigate the relationship between radiotherapy (RT), in particular chest RT, and development of immune-related (IR) pneumonitis in non-small-cell lung cancer (NSCLC) patients treated with anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1). PATIENTS AND

methodsBetween June 2011 and July 2017, NSCLC patients treated with anti-PD-1/PD-L1 at a tertiary-care academic cancer center were identified. Patient, treatment, prior RT (intent, technique, timing, courses), and IR pneumonitis details were collected. Treating investigators diagnosed IR pneumonitis clinically. Diagnostic IR pneumonitis scans were overlaid with available chest RT plans to describe IR pneumonitis in relation to prior chest RT. We evaluated associations between patient, treatment, RT details, and development of IR pneumonitis by Fisher exact and Wilcoxon rank-sum tests.

resultsOf the 188 NSCLC patients we identified, median follow-up was 6.78 (range, 0.30-79.3) months and median age 66 (range, 39-91) years; 54% (n = 102) were male; and 42% (n = 79) had stage I-III NSCLC at initial diagnosis. Patients received anti-PD-1/PD-L1 monotherapy (n = 127, 68%) or PD-1/PD-L1-based combinations (n = 61, 32%). In the entire cohort, 70% (132/188) received any RT, 53% (100/188) chest RT, and 37% (70/188) curative-intent chest RT. Any grade IR pneumonitis occurred in 19% (36/188; 95% confidence interval, 13.8-25.6). Of those who developed IR pneumonitis and received chest RT (n = 19), patients were more likely to have received curative-intent versus palliative-intent chest RT (17/19, 89%, vs. 2/19, 11%; P = .051). Predominant IR pneumonitis appearances were ground-glass opacities outside high-dose chest RT regions.

conclusionNo RT parameter was significantly associated with IR pneumonitis. On subset analysis of patients who developed IR pneumonitis and who had received prior chest RT, IR pneumonitis was more common in patients who received curative-intent chest RT. Attention should be paid to NSCLC patients receiving curative-intent RT followed by anti-PD-1/PD-L1 agents.

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarcinoma, Non-Small-Cell LungDrug-Related Side Effects and Adverse ReactionsFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humandurvalumabNivolumabPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 ReceptorAnti–PD-1/PD-L1 therapyNivolumabPembrolizumabPneumonitisRadiation

Identifiers

PMID31031204
PMCPMC8767572
OpenAlexW2927363814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.